background
chlamydia
pneumonia
frequent
caus
agent
acut
respiratori
diseas
recent
report
possibl
caus
asthma
object
assess
preval
c
pneumonia
infect
adult
patient
acut
exacerb
asthma
method
one
hundr
sixtyeight
adult
patient
acut
exacerb
asthma
control
subject
match
age
sex
smoke
statu
studi
nasopharyng
swab
specimen
obtain
subject
analyz
isol
cell
cultur
polymeras
chain
reaction
pcr
test
c
pneumonia
serum
sampl
also
obtain
test
c
pneumoniaespecif
antibodi
microimmunofluoresc
test
result
c
pneumonia
isol
two
asthma
patient
none
control
detect
pcr
nine
case
one
control
cultur
posit
specimen
also
posit
pcr
serolog
evid
acut
c
pneumonia
infect
present
asthma
patient
three
control
p
preval
c
pneumoniaespecif
igg
iga
significantli
higher
asthma
case
control
igg
versu
p
iga
versu
p
mean
titer
igg
iga
also
significantli
greater
asthma
case
control
igg
versu
p
iga
versu
p
asthma
chronic
lung
diseas
character
airway
obstruct
inflamm
bronchial
hyperrespons
varieti
stimuli
includ
infect
infect
virus
respiratori
syncyti
viru
parainfluenza
viru
influenza
b
viru
coronaviru
adenoviru
rhinoviru
identifi
children
adult
acut
exacerb
asthma
infect
organ
mycoplasma
pneumonia
also
associ
acut
exacerb
asthma
anoth
atyp
respiratori
pathogen
chlamydia
pneumonia
establish
import
caus
acut
respiratori
ill
includ
pharyng
bronchiti
pneumonia
previou
prospect
studi
design
assess
role
acut
c
pneumonia
infect
bronchiti
atyp
pneumonia
hahn
et
al
report
associ
serolog
evid
acut
c
pneumonia
infect
adultonset
asthma
asthmat
bronchiti
emr
et
al
also
examin
preval
c
pneumonia
infect
children
acut
exacerb
reactiv
airway
diseas
c
pneumonia
isol
children
studi
studi
role
c
pneumonia
acut
exacerb
adult
asthma
assess
frequenc
c
pneumonia
infect
adult
patient
exacerb
asthma
isol
polymeras
chain
reaction
pcr
nasopharyng
swab
serolog
patient
studi
adult
year
age
mean
year
male
femal
asthma
recurr
episod
revers
wheez
breathless
seen
kawasaki
medic
school
hospit
januari
decemb
acut
wheez
attack
often
statu
asthmaticu
initi
mean
percent
predict
fev
rang
sd
mean
durat
wheez
year
rang
year
patient
regular
treatment
bronchodil
twenti
eight
percent
current
smoker
exsmok
never
smoke
nonasthmat
control
match
age
sex
smoke
statu
select
patient
attend
hospit
criteria
inclus
sign
symptom
acut
respiratori
ill
normal
pulmonari
function
test
percent
predict
fev
greater
mean
rang
sd
inform
consent
obtain
subject
mean
durat
follow
month
rang
month
cultur
pcr
nasopharyng
swab
specimen
obtain
patient
control
isol
cell
cultur
pcr
swab
specimen
place
sucrosephosphateglutam
spg
transport
medium
cultur
c
pneumonia
perform
cycloheximidetr
cell
grown
cell
cultur
plate
report
previous
specimen
pass
cultur
confirm
done
fluorescentantibodi
stain
c
pneumonia
speciesspecif
genusspecif
monoclon
antibodi
c
pneumoniaespecif
primer
use
pcr
dna
base
sequenc
within
protein
gene
report
previous
cell
cultur
grown
c
pneumonia
strain
use
posit
control
chlamydia
transport
medium
use
neg
control
everi
run
electrophoresi
amplif
product
agaros
gel
v
band
visual
stain
ethidium
bromid
appear
base
pair
amplif
product
taken
posit
serolog
pair
serum
sampl
collect
interv
week
control
also
serum
sampl
asthma
patient
collect
sever
time
least
week
onset
sera
store
test
microimmunofluoresc
mif
test
use
titrat
igg
iga
igm
antibodi
chlamydi
speci
use
formalin
elementari
bodi
c
pneumonia
c
trachomati
c
psittaci
strain
antigen
rheumatoid
factor
absorb
gullsorb
gull
laboratori
salt
lake
citi
usa
iga
igm
titrat
acut
current
infect
defin
igm
demograph
characterist
studi
popul
shown
tabl
signific
differ
case
control
age
sex
smoke
statu
c
pneumonia
isol
nasopharynx
asthma
patient
none
control
c
pneumonia
detect
pcr
case
one
control
cultur
posit
specimen
posit
pcr
antibodi
c
pneumonia
shown
tabl
respiratori
tract
pathogen
includ
virus
pneumonia
identifi
patient
serolog
test
fourteen
found
infect
virus
seven
influenza
three
parainfluenza
three
respiratori
syncyti
viru
one
dual
infect
influenza
adenoviru
seven
pneumonia
dual
infect
c
pneumonia
virus
pneumonia
observ
result
laboratori
test
treatment
nine
cultur
pcrposit
patient
summar
tabl
five
nine
patient
cultur
pcr
posit
serolog
evid
acut
infect
three
patient
stabl
igg
antibodi
titer
iga
one
igg
iga
antibodi
four
patient
howev
clinic
laboratori
evid
infect
symptom
acut
respiratori
tract
infect
elev
inflammatori
sign
crp
esr
c
pneumonia
success
erad
nasopharynx
infect
patient
follow
antibiot
therapi
five
patient
treat
new
macrolid
antibiot
clarithromycin
four
roxithromycin
one
four
patient
levofloxacin
day
tabl
nine
patient
treat
combin
therapi
intraven
theophyllin
nine
patient
cours
oral
prednison
six
patient
antibiot
sever
asthma
attack
achiev
remiss
monia
respiratori
infect
acut
exacerb
asthma
antibodi
titer
wheez
studi
exacerb
asthma
associ
c
pneumonia
seen
often
older
age
group
exacerb
asthma
associ
c
pneumonia
antibodi
seen
often
young
adult
seroepidemiolog
studi
show
older
patient
like
reinfect
c
pneumonia
younger
patient
like
primari
infect
studi
patient
acut
c
pneumonia
infect
igm
antibodi
titer
suggest
reinfect
patient
sampl
size
studi
small
confirm
epidemiolog
observ
suggest
presenc
serum
iga
antibodi
use
marker
diagnosi
chronic
bacteri
infect
half
life
serum
iga
less
week
therefor
continu
presenc
may
indic
persist
antigen
stimul
immun
system
support
iga
antibodi
marker
chronic
infect
microbespecif
serum
iga
shown
associ
varieti
chronic
ill
bacteri
pathogen
includ
c
trachomati
particular
c
pneumoniaespecif
iga
associ
c
pneumonia
reinfect
chronic
obstruct
pulmonari
diseas
symptomat
asthma
data
also
show
signific
associ
c
pneumoniaespecif
serum
iga
antibodi
symptomat
revers
airway
obstruct
adult
find
indic
chronic
infect
reinfect
c
pneumonia
common
asthma
patient
asthma
exacerb
patient
evid
c
pneumonia
infect
occur
older
age
infect
c
pneumonia
often
reinfect
propos
chronic
c
trachomati
infect
induc
immunopatholog
diseas
reinfect
c
pneumonia
may
therefor
trigger
immunopatholog
process
lung
perhap
involv
epitheli
damag
mediat
releas
induc
delay
hypersensit
chlamydi
protein
antigen
result
chronic
airway
inflamm
characterist
asthma
rate
infect
virus
pneumonia
studi
similar
report
remark
lower
comparison
report
low
preval
viral
mycoplasm
infect
found
studi
probabl
due
use
cf
test
low
sensit
specif
conclus
shown
associ
c
pneumonia
acut
exacerb
asthma
asthmat
adult
abl
assess
whether
erad
c
pneumonia
antichlamydi
therapi
produc
improv
asthma
symptom
bronchodil
corticosteroid
also
use
